ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1004

SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis

Raquel Granados1, lourdes Ladehesa-Pineda2, Maria Angeles Puche Larrubia3, Maxime Dougados4, Eduardo Collantes5 and Clementina Lopez-Medina6, 1Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, 2Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, 3Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, 4Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, 5IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 6Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain

Meeting: ACR Convergence 2022

Keywords: Psoriatic arthritis, spondyloarthritis, Spondyloarthropathies

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Spondyloarthritis, (axial (axSpA), peripheral (pSpA)) and psoriatic arthritis (PsA)) share enthesitis as a hallmark clinical feature. Reliable clinical instruments have been developed to assess enthesitis: Spondyloarthritis Research Consortium of Canada Enthesitis (SPARCC), Leeds Enthesitis Index (LEI), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and Mander Enthesitis Index (MEI). Since these four indexes include different enthesis locations, they may capture a different number of patients with enthesitis in the different SpA entities.

For that, the purpose of the study is a) to describe the individual locations of enthesitis in axSpA, pSpA and PsA; b) to evaluate whether the prevalence of patients with at least one enthesitis across the three groups differs depending on the use of SPARCC, LEI, MASES and MEI indexes; c) to evaluate the level of agreement between these indexes for detecting patients with at least one enthesitis in axSpA, pSpA and PsA populations.

Methods: 4185 patients from the cross-sectional ASAS-PerSpA study with a diagnosis of axSpA (2719), pSpA (433) and PsA (1033) according to the Rheumatologist were included. The location of enthesitis during the study visit were evaluated according to the four indexes. The prevalence of patients with at least one enthesitis according to the different indexes were compared across the three diseases and pair-wise agreement between indexes were evaluated using the Cohen’s kappa.

Results: In the overall population, 10.7%, 8.3%, 13.5% and 17.2% of patients showed at least one enthesitis according to the SPARCC, LEI, MASES and MEI indexes, respectively. Figure 1 shows that, among patients with axSpA, MEI and MASES indexes capture the majority of patients with at least one enthesitis (98.7% and 82.4%, respectively), while in pSpA and PsA, MEI and SPARCC are the indexes which capture the majority of patients with enthesitis (100% and 84.6% for MEI and SPARCC in pSpA, and 97.3% and 77% for MEI and SPARCC in PsA, respectively). In the total population, MASES and MEI showed the strongest agreement for patients with at least one enthesitis (absolute agreement 96.3%; Cohen’s kappa: 0.86). Similar results were found among axSpA patients (97.3%; 0.90). In pSpA patients, SPARCC and MEI showed the strongest agreement (97.2%; 0.90), as well as among PsA patients (95.4%; 0.82).

Conclusion: The most prevalent locations of enthesitis on the global SpA population are the lumbar spinous processes, the thoracic spinous processes and Achilles tendon. MEI and MASES are the two indexes that capture more patients with enthesitis in axSpA, while MEI and SPARCC are the two indexes that capture more patients in pSpA and PsA. The LEI index may underestimate the prevalence of enthesitis in these patients. MASES and MEI showed the largest level of agreement in the overall population and in axSpA, while MEI and SPARCC showed the largest level of agreement in pSpA and PsA. These results suggest that the prevalence of enthesitis across entities differs depending on the disease and on the use of the different indexes.

Supporting image 1

Figure 1. Prevalence of enthesitis captured by different indexes.


Disclosures: R. Granados, None; l. Ladehesa-Pineda, None; M. Puche Larrubia, None; M. Dougados, Novartis, AbbVie, Eli Lilly, Merck, Pfizer, UCB Pharma; E. Collantes, None; C. Lopez-Medina, None.

To cite this abstract in AMA style:

Granados R, Ladehesa-Pineda l, Puche Larrubia M, Dougados M, Collantes E, Lopez-Medina C. SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/sparcc-mases-lei-and-mei-indexes-capture-different-patients-with-enthesitis-in-axial-spondyloarthritis-peripheral-spondyloartrhitis-and-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sparcc-mases-lei-and-mei-indexes-capture-different-patients-with-enthesitis-in-axial-spondyloarthritis-peripheral-spondyloartrhitis-and-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology